A Phase II Open Label Study of the Safety, Pharmacokinetics, and Efficacy of a True Human Anti-Inflammatory Therapeutic Antibody (RA-18C3) in Subjects With Moderate to Severe Acne Vulgaris
Phase of Trial: Phase II
Latest Information Update: 15 Jun 2015
Price : $35 *
At a glance
- Drugs Bermekimab (Primary)
- Indications Acne vulgaris
- Focus Adverse reactions
- Sponsors XBiotech
- 15 Jun 2015 Positive results of this study have been published on the June 2015 issue of Journal of Drugs in Dermatology.
- 15 Jun 2015 Positive results from this study published in an XBiotech Media Release.
- 16 Oct 2014 New trial record